Literature DB >> 2373871

Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA.

H H Lee1, S H Weiss, L S Brown, D Mildvan, V Shorty, L Saravolatz, A Chu, H M Ginzburg, N Markowitz, D C Des Jarlais.   

Abstract

Seroprevalence of human immunodeficiency virus type 1 (HIV-1) and human T lymphotropic virus types I and II (HTLV-I/II) was determined among 1160 intravenous (iv) drug abusers from five drug treatment or medical centers (Manhattan, Brooklyn, New Jersey, Detroit, and New Orleans). HIV-1 infection ranged from 5% in New Orleans to 48% in New York City. Hispanics and blacks had a significantly higher rate of HIV-1 infection than whites (P less than .01), but within each group rates were similar between males and females and by age stratum. HTLV-I/II seroprevalence increased with age from 3% in the 20-29 year age group to 37% in the group greater than 50 years. New Orleans and Manhattan (24%) had the highest rate, and blacks (19%) had a higher rate than either Hispanics (6.3%) or whites (7.3%). No association between HIV-1 and HTLV-I/II infection was observed except in Manhattan. When compared with iv drug abusers infected only with HIV-1, dually infected subjects had more clinical symptoms related to immune deficiency but a lower prevalence of HIV antigenemia. These data document the frequent occurrence of retroviral infections in iv drug abusers. The contrast between the two classes of virus suggests that HIV-1 is more efficiently transmitted, while the age-dependent rise in HTLV-I/II seroprevalence suggests cumulative exposure of a less-transmissible agent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373871     DOI: 10.1093/infdis/162.2.347

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay kits for detection of antibody to HTLV-I and -II.

Authors:  C Cossen; S Hagens; R Fukuchi; B Forghani; D Gallo; M Ascher
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Absence of HTLV-I and HTLV-II infection in prostitutes in the area of Seville, Spain.

Authors:  E J Calderón; E Gómez-Lucia; I Aguado; J A Pineda; M Essex; M Leal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-09       Impact factor: 3.267

3.  Prevalence of infection by human T-cell leukemia virus types I and II in southern Spain.

Authors:  E J Calderón; C Rey; F J Medrano; J Sánchez-Román; V Soriano; Y Torres; M Ruiz; E Lissen; M Leal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

4.  APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.

Authors:  Marcel Ooms; Aikaterini Krikoni; Andrea K Kress; Viviana Simon; Carsten Münk
Journal:  J Virol       Date:  2012-03-28       Impact factor: 5.103

5.  Evaluation of a p21e-spiked western blot (immunoblot) in confirming human T-cell lymphotropic virus type I or II infection in volunteer blood donors. The Retrovirus Epidemiology Donor Study Group.

Authors:  S H Kleinman; J E Kaplan; R F Khabbaz; M A Calabro; R Thomson; M Busch
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

6.  Seroprevalence of and risk factors for HIV-1 infection in injection drug users in Montreal and Toronto: a collaborative study.

Authors:  F Lamothe; J Bruneau; R Coates; J G Rankin; J Soto; R Arshinoff; M Brabant; J Vincelette; M Fauvel
Journal:  CMAJ       Date:  1993-10-01       Impact factor: 8.262

7.  HTLV-II among Italian intravenous drug users and hemophiliacs.

Authors:  A R Zanetti; G Zehender; E Tanzi; C Galli; G Rezza; A Cargnel; A Boschini; D Mari; G Pizzocolo; F Mazzotta
Journal:  Eur J Epidemiol       Date:  1992-09       Impact factor: 8.082

8.  Prevalence of antibody to human T-cell lymphotropic virus type I/II in people of Caribbean origin in Toronto.

Authors:  J Chiavetta; J Nusbacher; F Tam; A Wall; J Steaffens; H Lee
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

9.  HTLV-I and HTLV-II infections among HIV-1 seropositive patients in Sao Paulo, Brazil.

Authors:  A C de Araujo; J S Casseb; E Neitzert; M L de Souza; F Mammano; A Del Mistro; A De Rossi; L Chieco-Bianchi
Journal:  Eur J Epidemiol       Date:  1994-04       Impact factor: 8.082

10.  Seroepidemiology of viral infections among intravenous drug users in northern California.

Authors:  J B Zeldis; S Jain; I K Kuramoto; C Richards; K Sazama; S Samuels; P V Holland; N Flynn
Journal:  West J Med       Date:  1992-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.